Regulatory Submissions for Shelf Life Extensions

Regulatory Submissions for Shelf Life Extensions in Pharmaceuticals

Extending the shelf life of a pharmaceutical product can lead to improved supply chain efficiency, reduced waste, and enhanced profitability. However, shelf life extensions must be scientifically justified and formally submitted to health authorities. Whether in the United States, European Union, or WHO-regulated territories, these extensions require thorough stability data, risk assessments, and updates to the regulatory dossier.
Click to read the full article.

Regulatory Submissions for Shelf Life Extensions, Shelf Life and Expiry

How to Prepare a Regulatory Submission for Shelf Life Extension

Regulatory submission for shelf life extension may be required in various scenarios:
Click to read the full article.

Regulatory Submissions for Shelf Life Extensions, Shelf Life and Expiry

Checklist for Extending Expiry Dates in Global Markets

Before doing anything regulatory, initiate a formal change control within your Quality Management System (QMS).
Click to read the full article.

Regulatory Submissions for Shelf Life Extensions, Shelf Life and Expiry

Step-by-Step Guide to Updating Labeling Based on New Shelf Life

The labeling update process begins with formal change control:
Click to read the full article.

Regulatory Submissions for Shelf Life Extensions, Shelf Life and Expiry

Documenting New Stability Data for Extension Requests

Regulators require real-time, post-approval stability data that reflects actual commercial production. Key considerations include:
Click to read the full article.

Regulatory Submissions for Shelf Life Extensions, Shelf Life and Expiry

Regulatory Differences in Shelf Life Extension Across Regions

Global commercialization of a drug means maintaining consistency in shelf life while complying with country-specific requirements. Failure to understand regulatory nuances can lead to:
Click to read the full article.

Regulatory Submissions for Shelf Life Extensions, Shelf Life and Expiry

FDA and EMA Guidance on Post-Approval Shelf Life Changes

Shelf life affects the safety, efficacy, and commercial viability of a drug product. Both the FDA and EMA mandate that any change to the approved shelf life must be justified with real-time stability data generated using validated methods. These changes typically fall under “post-approval changes” and require proper variation submissions or supplements.
Click to read the full article.

Regulatory Submissions for Shelf Life Extensions, Shelf Life and Expiry

Creating a Bridging Study to Support Shelf Life Extension

A bridging study is a scientific approach that compares the stability of a current product or batch with historical data from previously tested batches. It aims to demonstrate that the new material behaves similarly under storage conditions, allowing regulators to accept shelf life extensions based on prior data.
Click to read the full article.

Regulatory Submissions for Shelf Life Extensions, Shelf Life and Expiry

Preparing a Justification Report for Shelf Life Changes

The justification report provides a clear scientific rationale for the proposed change in expiry date. It summarizes historical and current stability data, demonstrates consistency across batches, and confirms compliance with ICH and regulatory requirements.
Click to read the full article.

Regulatory Submissions for Shelf Life Extensions, Shelf Life and Expiry

Real-World Cases of Successful Shelf Life Extensions

Extending expiry dates not only enhances supply chain flexibility but also reduces the frequency of manufacturing and packaging runs. Key drivers include:
Click to read the full article.

Regulatory Submissions for Shelf Life Extensions, Shelf Life and Expiry